Chakraborty, Debdulal http://orcid.org/0000-0001-9693-7882
Mondal, Soumen
Parachuri, Nikulaa
Kumar, Nilesh http://orcid.org/0000-0002-7439-2081
Sharma, Ashish http://orcid.org/0000-0002-8550-9791
Article History
Received: 24 September 2021
Revised: 6 October 2021
Accepted: 6 October 2021
First Online: 13 October 2021
Competing interests
: DC: CONSULTANT: for Novartis, Bayer, Intas. AS: CONSULTANT: for Novartis, Allergan, Bayer, Intas and Lupin. The remaining authors declared no competing interests.